NextCure Company Insiders
NXTC Stock | USD 1.17 0.03 2.50% |
NextCure's insiders are aggressively buying. The analysis of the overall insider sentiment regarding NextCure suggests that all insiders are extremely bullish. NextCure employs about 82 people. The company is managed by 12 executives with a total tenure of roughly 192 years, averaging almost 16.0 years of service per executive, having 6.83 employees per reported executive.
NextCure's Insider Buying Vs Selling
100
Selling | Buying |
Latest Trades
2019-11-15 | Sofinnova Venture Partners Ix, | Acquired 150000 @ 36.75 | View | ||
2019-05-13 | X L.P. Canaan | Acquired 50000 @ 15 | View |
Monitoring NextCure's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
NextCure |
NextCure Management Team Effectiveness
The company has return on total asset (ROA) of (0.3109) % which means that it has lost $0.3109 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5475) %, meaning that it created substantial loss on money invested by shareholders. NextCure's management efficiency ratios could be used to measure how well NextCure manages its routine affairs as well as how well it operates its assets and liabilities. As of November 29, 2024, Return On Tangible Assets is expected to decline to -0.51. In addition to that, Return On Capital Employed is expected to decline to -0.59. At present, NextCure's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 200.8 M, whereas Net Tangible Assets are forecasted to decline to about 173.2 M.As of November 29, 2024, Common Stock Shares Outstanding is expected to decline to about 23 M. In addition to that, Net Loss is expected to decline to about (70.6 M)
NextCure Workforce Comparison
NextCure is regarded fourth in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 776. NextCure retains roughly 82.0 in number of employees claiming about 11% of equities under Health Care industry.
NextCure Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific NextCure insiders, such as employees or executives, is commonly permitted as long as it does not rely on NextCure's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, NextCure insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Feigal Ellen over a week ago Acquisition by Feigal Ellen of 14250 shares of NextCure subject to Rule 16b-3 | ||
Jones Elaine V over two months ago Acquisition by Jones Elaine V of 14250 shares of NextCure at 1.62 subject to Rule 16b-3 | ||
Jones Elaine V over three months ago Acquisition by Jones Elaine V of 14250 shares of NextCure at 4.77 subject to Rule 16b-3 | ||
Kabakoff David S over three months ago Acquisition by Kabakoff David S of 28050 shares of NextCure at 1.5 subject to Rule 16b-3 | ||
Cobourn Steven P. over six months ago Acquisition by Cobourn Steven P. of 100000 shares of NextCure at 12.59 subject to Rule 16b-3 | ||
Cobourn Steven P. over six months ago Acquisition by Cobourn Steven P. of 93900 shares of NextCure at 2.23 subject to Rule 16b-3 | ||
Langermann Sol over six months ago Acquisition by Langermann Sol of 117375 shares of NextCure subject to Rule 16b-3 | ||
Nicholson Garry A over a year ago Acquisition by Nicholson Garry A of 14250 shares of NextCure subject to Rule 16b-3 |
NextCure Notable Stakeholders
A NextCure stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as NextCure often face trade-offs trying to please all of them. NextCure's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting NextCure's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
CPA CPA | Chief Officer | Profile | |
Steven CPA | Chief Officer | Profile | |
Sebastien Maloveste | Senior Development | Profile | |
Sourav Kundu | Senior Manufacturing | Profile | |
Kevin Shaw | General Counsel | Profile | |
Michael MSBA | CEO, CoFounder | Profile | |
Lieping MD | CoFounder Board | Profile | |
Timothy Mayer | Chief Officer | Profile | |
MD FACP | Chief Officer | Profile | |
Udayan MD | Senior Development | Profile | |
Solomon Langermann | Chief Officer | Profile | |
Stacy Rollinger | Vice Resources | Profile |
About NextCure Management Performance
The success or failure of an entity such as NextCure often depends on how effective the management is. NextCure management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of NextCure management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the NextCure management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.49) | (0.51) | |
Return On Capital Employed | (0.56) | (0.59) | |
Return On Assets | (0.49) | (0.51) | |
Return On Equity | (0.55) | (0.52) |
Please note, the presentation of NextCure's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, NextCure's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of NextCure's management manipulating its earnings.
NextCure Workforce Analysis
Traditionally, organizations such as NextCure use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare NextCure within its industry.NextCure Manpower Efficiency
Return on NextCure Manpower
Revenue Per Employee | 0.0 | |
Revenue Per Executive | 0.0 | |
Net Loss Per Employee | 764.9K | |
Net Loss Per Executive | 5.2M | |
Working Capital Per Employee | 1.3M | |
Working Capital Per Executive | 8.8M |
Complementary Tools for NextCure Stock analysis
When running NextCure's price analysis, check to measure NextCure's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NextCure is operating at the current time. Most of NextCure's value examination focuses on studying past and present price action to predict the probability of NextCure's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NextCure's price. Additionally, you may evaluate how the addition of NextCure to your portfolios can decrease your overall portfolio volatility.
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |